Dr Reddy's Granted 30 Days to Liquidate 'Olymviq' Inventory Amid Novo Trademark Dispute

Dr. Reddy's Laboratories Faces Trademark Dispute with Novo Nordisk

Key Developments:

• Dr. Reddy's Laboratories has been ordered to discontinue the use of the trademark "Olymviq" for its semaglutide drug within 30 days.
• The company has undertaken to sell its existing stock of "Olymviq" within the same timeframe.

Background:

Read also: Expert Portfolio Manager Raja Venkatraman Names Top Investment Picks for June 4

The Delhi High Court has intervened in a trademark dispute between Dr. Reddy's Laboratories and Novo Nordisk, with the former agreeing to cease the use of the trademark "Olymviq". The dispute is related to the sale of semaglutide, a drug also marketed by Novo Nordisk under a different brand name.

Implications:

The discontinuation of the "Olymviq" brand will likely result in significant changes to Dr. Reddy's Laboratories' sales strategy and revenue projections. The company will need to adapt to the new brand name and potentially adjust its marketing efforts to minimize disruption to customers and investors.